BlackRock’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BlackRock’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-601	Closed	-$59K	–	3339
2015 Q1	$59K	Hold	601	–	–	﹤0.01%	1885
2014 Q4	$56K	Hold	601	–	–	﹤0.01%	1909
2014 Q3	$41K	Hold	601	–	–	﹤0.01%	2010
2014 Q2	$63K	Sell	601 -31	-5%	-$2.64K	﹤0.01%	1841
2014 Q1	$52K	Sell	632 -28,455	-98%	-$2.63M	﹤0.01%	1908
2013 Q4	$1.88M	Buy	29,087 +28,649	+6,541%	+$1.7M	﹤0.01%	1037
2013 Q3	$28K	Hold	438	–	–	﹤0.01%	2106
2013 Q2	$18K	Buy	+438	New	+$20K	﹤0.01%	2372

BlackRock's GEVA Position: Q2 2015 in Review

BlackRock sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 601 shares — an estimated $59K sold.

BlackRock first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.88M in Q4 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

BlackRock reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
BlackRock sold 601 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $59K.
BlackRock first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
BlackRock's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.88M in Q4 2013.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BlackRock's 13F filing for Q2 2015, filed 7 Aug 2015.